---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-064863"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2026-05-21T11:34:37+00:00"
generated_at: "2026-05-21T11:40:49.625411+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics completes productive FDA meeting for zervimesine in DLB psychosis

## Summary
- FDA meeting held May 20, 2026 to review Phase 2 SHIMMER study results and registrational study design.
- Company believes it has a path forward for zervimesine (CT1812) to treat dementia with Lewy bodies patients with psychosis.
- Formal FDA minutes expected in June 2026.
- Cognition Therapeutics (NASDAQ: CGTX) is a clinical-stage company developing neurodegenerative disorder treatments.

## SEC filing metadata
- accession: 0001104659-26-064863
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2026-05-21T11:34:37+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465926064863/0001104659-26-064863-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465926064863/tm2615260d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-064863
- JSON: https://secwatch.observer/filing/0001104659-26-064863.json
- Plain text: https://secwatch.observer/filing/0001104659-26-064863.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.